Related Experiment Video
Updated: Jan 1, 2026
Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping
Published on: August 12, 2019
Assessing Discrepancies in Neurocognitive and Patient-Reported Measures of Brain Tumor Survivors
Deborah Allen1, Barbara W Carlson2, John R Carlson
1Duke University Health System.
Objectives:
To examine the association between performance-based neurocognitive and patient-reported cognitive function tests and identify characteristics that may explain observed discrepancies as a means to advance intervention development.
Sample & Setting:
40 adults diagnosed with a primary brain tumor (PBT) (high-grade, n = 35) were recruited from two academic neuro-oncology clinics in North Carolina.
Methods & Variables:
Eligibility included a Mini-Mental State Examination score of 24 or greater, having completed cancer treatment, and having tumor stability. Participants completed performance-based neurocognitive and patient-reported cognitive function, demographic, and symptom assessment tests at one time point.
Results:
Neurocognitive impairments included executive control, memory, and attention. Age, time since diagnosis, and tumor- or treatment-specific variables were not associated with neurocognitive or patient-reported cognitive function. Those reporting worse cognitive impairment tended also to report greater severity of PBT-specific and depressive symptoms.
Implications For Nursing:
Patient-reported cognitive concerns warrant additional assessment for potential interventions to maintain function.
